Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Tax Provisions: 2014-2025

Historic Tax Provisions for Enanta Pharmaceuticals (ENTA) over the last 12 years, with Sep 2025 value amounting to -$80,000.

  • Enanta Pharmaceuticals' Tax Provisions rose 85.61% to -$80,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year increase of 8.47%. This contributed to the annual value of -$1.8 million for FY2025, which is 8.47% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Tax Provisions stood at -$80,000, which was down 375.86% from $29,000 recorded in Q2 2025.
  • Enanta Pharmaceuticals' Tax Provisions' 5-year high stood at $7.1 million during Q1 2021, with a 5-year trough of -$9.4 million in Q2 2021.
  • For the 3-year period, Enanta Pharmaceuticals' Tax Provisions averaged around -$77,545, with its median value being -$395,000 (2024).
  • The largest annual percentage gain for Enanta Pharmaceuticals' Tax Provisions in the last 5 years was 1,044.30% (2023), contrasted with its biggest fall of 70,400.00% (2023).
  • Over the past 5 years, Enanta Pharmaceuticals' Tax Provisions (Quarterly) stood at -$36,000 in 2021, then rose by 5.56% to -$34,000 in 2022, then crashed by 1,729.41% to -$622,000 in 2023, then soared by 33.12% to -$416,000 in 2024, then surged by 85.61% to -$80,000 in 2025.
  • Its Tax Provisions was -$80,000 in Q3 2025, compared to $29,000 in Q2 2025 and -$1.3 million in Q1 2025.